Karyopharm Therapeutics Inc. · NASDAQ:KPTI
Karyopharm Therapeutics — Q1 2020 Earnings Presentation
20 slides from Karyopharm Therapeutics's earnings presentation, May 5, 2020
Slide 1: Investor Conference Call: First Quarter 2020 Financial Results and Business Update
Investor Conference Call: First Quarter 2020 Financial Results and Business Update May 5, 2020
Slide 2: On Today's Call
On Today’s Call • Michael G. Kauffman, MD, PhD, Chief Executive Officer Prepared • John Demaree, Chief Commercial Officer Remarks • Mike Mason, MBA, Chief Financial Officer • Sharon Shacham, PhD, President and Chief Scientific Officer • Christopher Primiano, JD, MBA, Chief Business Officer & General
Slide 3: Forward-looking Statements and Other Important Information
Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm’s expectatio
Slide 4: Significant Progress Made Despite Industry-Wide Challenges from the COVID-19 Pandemic
Significant Progress Made Despite Industry-Wide Challenges from the COVID-19 Pandemic Pipeline / Clinical Corporate Development Commercial Update Data Update and Balance Sheet • Q1 2020 XPOVIO net sales of $16.1M • Positive top-line BOSTON Phase 3 • Expanded territory rights with Antengene (total re
Slide 5: XPOVIO Quarterly Sales
XPOVIO Quarterly Sales XPOVIO Product Sales Following Launch • >2,200 prescriptions (RX) filled through March 31, 2020 • Minimal inventory build in Net Sales ($M) distribution channel in Q1 2020 $17.7M Inventory Sales $16.1M • Prescription demand approximately flat Q1 2020 $12.8M Inventory vs. Q4 20
Slide 6: XPOVIO Patient Experience Continues to be Highly Positive
XPOVIO Patient Experience Continues to be Highly Positive STORM Study1 Real World Experience July 2019 – March 20202 >97% of RXs received to date • 26% overall response rate have been approved / reimbursed by • 39% of patients had minimal response payers or better ~60% of • Median duration of treatm
Slide 7: COVID-19 Pandemic Impact on XPOVIO Commercial Market
COVID-19 Pandemic Impact on XPOVIO Commercial Market Advantages of XPOVIO as Patients and Commercial Pressures Physicians Seek to Limit Visits to the Hospital • Industry as a whole, including oncologists, • Oral administration, delivered directly to report fewer visits for non COVID-19 patients pati
Slide 8: Karyopharm is Working To Mitigate the Commercial Impact of the COVID-19 Pandemic
Karyopharm is Working To Mitigate the Commercial Impact of the COVID-19 Pandemic Key Responses • Rapidly launched multiple digital tools to facilitate continued sales force engagement with customers • Extensive email campaign • Multiple e-detailing platforms (Zoom, Veeva Engage) • Moved peer-to-peer
Slide 9: Top-Line Data from the Phase 3 BOSTON Study
Top-Line Data from the Phase 3 BOSTON Study Median Progression Free Survival (PFS) 16 Safety 13.93 14 • No new safety signals in patients 12 treated in the SVd arm PFS (Months) 10 9.46 • No imbalance of patient deaths across both treatment arms 8 - Fewer deaths numerically in the SVd arm 6 +47% • Mo
Slide 10: In BOSTON Study, SVd Arm Had Lower Rates of Peripheral Neuropathy Compared to Vd
In BOSTON Study, SVd Arm Had Lower Rates of Peripheral Neuropathy Compared to Vd Arm and Triplet-Vd Regimens Seen Across Other Phase 3 Trials • Peripheral neuropathy (PN) is amongst the most common causes of treatment limitation and discontinuation of Vd and combination Vd regimens • The actual rate
Slide 11: MM Patients Treated by Line of Therapy (U.S.)
MM Patients Treated by Line of Therapy (U.S.) Estimated U.S. Multiple Myeloma Patients Treated by Line of Therapy, 2019 Average Time on Therapy ~69,000 ~31,000 1L Patients ++++ Patients by Treated With Drug Therapy Line of in 2019 Treatment ~20,000 2L +++ ~12,000 3L ++ An additional 60,000+ patients
Slide 12: Karyopharm Initiates New Study of Low-dose Selinexor in Patients with Severe COVID-19
Karyopharm Initiates New Study of Low-dose Selinexor in Patients with Severe COVID-19 Scientific Rationale for Evaluating Selinexor in COVID-19 • XPO1 inhibitors have previously demonstrated preclinical activity against >20 viruses, including influenza, RSV and other viral respiratory infections • X
Slide 13: A Phase 2 Randomized, Single-Blind Study of Low Dose Oral Selinexor in Severe COVID-19
A Phase 2 Randomized, Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor in Patients with Severe COVID-19 (NCT04349098) ~40 International Study Sites, ~10 countries Primary endpoints: Day 14 Ordinal Scale Improvement (OSI) Oral Selinexor Proportion of patients with at
Slide 14: Karyopharm's Novel Pipeline | Selinexor
Karyopharm’s Novel Pipeline | Selinexor Hematologic Malignancies - Selinexor Phase I Phase II Phase III Multiple Myeloma (relapsed/refractory) | STORM FDA Approved (Accelerated Approval)1 Multiple Myeloma (relapsed/refractory) | BOSTON2 Diffuse Large B-cell Lymphoma (relapsed/refractory) | SADAL PDU
Slide 15: Karyopharm's Novel Pipeline | Eltanexor, KPT-9274 and Verdinexor
Karyopharm’s Novel Pipeline | Eltanexor, KPT-9274 and Verdinexor Additional Oncology Programs - Eltanexor and KPT-9274 Phase I Phase II Phase III Myelodysplastic Syndromes (MDS) (single agent or in combination with hypomethylating agents)1 Drug: Eltanexor Colorectal Cancer (CRC) and Prostate Cancer
Slide 16: First Quarter Financial Results
First Quarter Financial Results Mike Mason Chief Financial Officer
Slide 17: First Quarter 2020 Financial Results
First Quarter 2020 Financial Results Three Months Ended Statement of Operations March 31st 2020 2019 Total Revenue $18.1M $0.2M XPOVIO Net Sales $16.1M --- License and Other Revenue $2.1M $0.2M Total Operating Expenses $65.5M $65.1M Cost of Sales $0.8M ---- Research and Development Expense $34.0M $3
Slide 18: Balance Sheet and Financial Guidance
Balance Sheet and Financial Guidance Balance Sheet March 31, 2020 December 31, 2019 Cash, Cash Equivalents, Restricted Cash $385.2M $265.8M and Investments • XPOVIO net sales in Q2 2020 expected to be slightly higher than Q1 2020 • Non-GAAP R&D and SG&A expenses are expected to be at the lower end o
Slide 19: Numerous Expected Key Milestones for XPOVIO / Selinexor in 2020
Numerous Expected Key Milestones for XPOVIO / Selinexor in 2020 Mid-Late 2020 1. BOSTON data presentation at ASCO 2020 2. sNDA submission based on data from BOSTON study 3. Regulatory decision from FDA based on DLBCL sNDA 4. U.S. commercial launch in DLBCL1 5. Initial results from COVID-19 clinical
Slide 20: Questions? Answers.
Questions? Answers. ©2020 Karyopharm Therapeutics Inc. 20
Karyopharm Therapeutics — Q1 2020 Earnings Presentation on 6ix